Dwaspasm F.C.Tablet

Dwaspasm F.C.Tablet
17 May

Dwaspasm F.C.Tablet

Antispasmodics

- Hyoscine N butylbromide has a peripheral anticholinergic action  
  which results from a ganglion-blocking action within the visceral  
  wall as well as from an anti-muscarinic activity. 
  Consequently, it exerts a spasmolytic action on the smooth 
  muscles of the gastrointestinal, biliary and genito-urinary tracts.
- As a quaternary ammonium derivative, Hyoscine N 
  butyl-bromide does not readily pass the blood-brain barrier; 
  therefore, anticholinergic side effects at the central nervous 
  system do not occur when used in therapeutic doses

Indecation

  Dwaspasm® is mainly indicated in the following cases:
- Gastrointestinal tract spasm (including pylorospasm).
- Hypermotility and postoperative vomiting and spastic   
  constipation.
- Spasm and dyskinesia of the biliary system.
- Genito-urinary tract spasm.
- Spastic pain in dysmenorrhoea and nocturnal enuresis.
- Delayed relaxation of the lower uterine segment.
- Peptic ulcer in conjunction with antacids or H2-receptor 
  antagonists. 
 

Dosage & Administration

 Adults: 1- 2 tablets of Dwaspasm® tablet three to five times 
  a day as needed.
- Children:  depending on age, the daily children dosage of   
  Dwaspasm® oral solution is recommended as follows:
  Children Over 6 years: 10 ml 3- 4 times daily.
  Children 1- 6 years: 5- 10 ml three times daily.
  Infants less than 1 year: 5 ml three times daily.
  Dwaspasm® can be taken both on empty and full stomach.
 

- Each film coated tablet of Dwaspasm® 10 contains:
  Hyoscine N butylbromide                       10 mg
- Each 5 ml of Dwaspasm® oral solution contains:
  Hyoscine N butylbromide                        5 mg
 

  Dwaspasm® is contraindicated in the following cases: 
- Hypersensitivity to Hyoscine N butyl bromide or any 
  anticholinergic drugs.
- Myasthenia gravis and megacolon.
- Tachycardia and myocardial Ischemia.
- Narrow angle glaucoma, adhesions between the Iris and lens.
- Gastrointestinal obstructive disease, paralytic ileus,  ulcerative 
  colitis and hepatic diseases.
- Obstructive uropathy and renal diseases.

 The effect of Dwaspasm® may be enhanced by concomitant 
   administration of other drugs with antimuscarinic properties 
  such as: Amantadine, Tricyclic antidepressants, Quinidine, some 
  Antihistamines, Phenothiazine and Antipsychotics. 
- Concomitant treatment with Dopamine antagonist such as 
   Metoclopramide may result in diminution of the effects of both 
  drugs on the gastrointestinal tract.
 

 Caution is recommended in pregnancy especially during the first 
  trimester.
- Safety during lactation has not yet been established.
  However, adverse effects on the new born have not been reported.
 

The side effects are dose-related and usually reversible when 
  therapy is discontinued.
  At therapeutic doses, adverse effects include: dryness of mouth 
  and skin, thirst, flushing, dilated pupils with loss of 
  accommodation and photophobia, transient bradycardia 
  followed by tachycardia, with palpitations and arrhythmias, and 
  difficulty in micturition. 
 Over-dosage:-
 In case of over-dosage, anti-cholinergic symptoms as urinary 
 retention, dry mouth, reddening of the skin, tachycardia and 
 transient visual disturbances may occur.  Treatment of the 
 over-dosage: gastric lavage with medicinal charcoal should be 
 followed by magnesium sulfate (15%). In addition, appropriate 
 supportive therapy should be given as required. 
 

  Dwaspasm® needs to be used with caution in:
- Patients prone to narrow angle glaucoma;
- Patients susceptible to intestinal or urinary outlet obstructions;
- In those inclined to tachyarrhythmia.
 

- Dwaspasm® tablet: Blister of 10 tablets, pack of two Blisters. 
- Dwaspasm® oral solution: bottles of 60 ml / 100 ml.
- Hospital packs of different sizes.
 

 Store in a dry place at a temperature not exceeding 25 °C